Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
341 to 360 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| R01CA238387 | Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer | 1 | 2025 |
| R01CA246547 | CD4+ T cells and neoantigens in melanoma immunotherapy. | 1 | 2025 |
| R01CA248731 | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | 1 | 2025 |
| R01CA248896 | Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer | 1 | 2025 |
| R01CA249393 | Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma | 1 | 2025 |
| R01CA250378 | Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma | 1 | 2025 |
| R01CA251930 | Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery | 1 | 2025 |
| R01CA252239 | Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | 1 | 2025 |
| R01CA254104 | Investigating Macrophage Molecular and Functional Diversity in Tumor Immunity | 1 | 2025 |
| R01CA255039 | Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma | 1 | 2025 |
| R01CA255450 | Delineating developmental programs driving tumorigenesis in triple-negative breast cancer | 1 | 2025 |
| R01CA257195 | Deciphering the molecular control of intratumoral dendritic cells | 1 | 2025 |
| R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 1 | 2025 |
| R01CA258297 | Precision targeting of T cell cytotoxicity with PET | 1 | 2025 |
| R01CA258524 | Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis | 1 | 2025 |
| R01CA260752 | Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment | 1 | 2025 |
| R01CA262121 | Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds | 1 | 2025 |
| R01CA262250 | CAR NKT Cell Immunotherapy of Neuroblastoma | 1 | 2025 |
| R01CA262425 | Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer | 1 | 2025 |
| R01CA266446 | The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=18